Evidence map›Paper›PMID 42389466›Full record

ArticleFrontiers in bioengineering and biotechnology2026

Engineering

Petra Štravs, Henri-Pierre Fierobe, Stéphanie Perret, Aleš Berlec

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Petra ŠtravsDepartment of Biotechnology, Jožef Stefan Institute, Ljubljana, Slovenia.
Henri-Pierre FierobeAix-Marseille Université, CNRS, LCB-UMR7283, Marseille, France.
Stéphanie PerretAix-Marseille Université, CNRS, LCB-UMR7283, Marseille, France.
Aleš BerlecDepartment of Biotechnology, Jožef Stefan Institute, Ljubljana, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lactic acid bacteria are commonly used to convert carbohydrates into valuable products like lactic acid, but they currently rely on carbon sources from food crops, raising sustainability and cost concerns. Lignocellulosic waste is a more sustainable alternative, yet these bacteria cannot naturally break down cellulose to grow on it. Efficient cellulose degradation requires synergetic action of multiple cellulolytic enzymes, each operating through distinct mechanisms. Methods: To design genetic constructs for co-expression of gene pairs encoding different heterologous cellulases (Cel5I, Cel5H or Cel9A) from separate expression cassettes in Results: The A1 strain that co-produced cellulase pair Cel5H-Cel9A achieved the highest activity on PASC and one of the highest activities measured on microcrystalline cellulose. Additionally, the A1 strain showed the highest degradation of PASC during the 16 days of anaerobic cultivation and one of the highest lactic acid production levels. Discussion: In this study, co-expression of gene pairs that encode different heterologous cellulases from separate promoters in

Indexed as

Cel5HCel5ICel9Acelluloseco-expressionendoglucanaseslactic acid bacteriasynergy

Identifiers

PMID42389466
PMCPMC13318888

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.